Expert Interview
A second opinion: Discussing the standard of care and the potential of Qulipta (Atogepant), a once-daily oral drug initially approved in 2021 for preventing episodic migraines that just got an expanded label to treat chronic migraines.
Ticker(s): ABBVInstitution: UCLA
- Professor of Neurology and Director of the UCLA Goldberg Migraine and Pain Program.
- His laboratory investigates basic mechanisms of migraine, with a focus of the identification of new therapies. Research interests include cellular neuroscience, neuropharmacology, and novel treatments for migraine and other headache disorders.
- Serves as associate editor of the journal Cephalalgia; has served on the Board or Trustees of the International Headache Society, and is presently on the Executive Board of Directors of the American Headache Society.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
